BODITECH MED INC.

Boditech Med Inc. (Korean Boditech) was established in 1998 and listed on the Korea Exchange (KOSDAQ) in 2015. The company's products have obtained certifications from FDA, CE, CFDA, KFDA, and JPAL, and are sold in over 120 countries worldwide. Its fluorescence immunoassay analyzers have been installed in more than 73,000 units globally. Korean Boditech adheres to the concept of respecting the value of life and has been dedicated to the research and development of in vitro diagnostic equipment and reagents for over two decades, striving to become a world-class in vitro diagnostic company. Boditech (Guangxi) Biotechnology Co., Ltd. was founded in 2016 and is an in vitro diagnostic enterprise integrating R&D, production, and sales. As a wholly-owned subsidiary of Korean Boditech, the company's R&D and production are in line with those of Korean Boditech. It adopts advanced Korean technology and imported raw materials, and has established its own domestic brand Aimayi. It continuously innovates in combination with the Chinese market and has developed multiple fluorescence immunoassay analyzers that meet market demands. Dijiboditech (Shanghai) Trading Co., Ltd. was jointly invested and established by Korean Boditech and Shanghai Dijixing Technology Development Co., Ltd. in 2017. The company is committed to developing the life health industry and focuses on the R&D, production, and sales of POCT products in the field of in vitro diagnostic reagents for biomedicine. It mainly promotes the AFIAS fluorescence immunoassay analyzer produced by Korean Boditech. Dijiboditech is the Chinese marketing center for the AFIAS fluorescence immunoassay analyzer series products.